Trial Profile

A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daclatasvir (Primary) ; Peginterferon alfa-2a; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use
Sponsors Bristol-Myers Squibb

Most Recent Events

28 Jun 2012 Planned number of patients changed from 48 to 65 as reported by EudraCT.
20 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.
17 Sep 2011 Results have been presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, according to a Bristol-Myers Squibb media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com